MCC950

SKU: orb1300375

Description

MCC950 sodium is a highly potent and selective NLRP3 inflammasome inhibitor, with IC50 values of 7.5 nM and 8.1 nM in mouse and human macrophages, respectively. It shows no activity against AIM2, NLRC4, or NLRP1 inflammasomes. This compound is widely used in research to investigate NLRP3-driven pathologies in both cellular and animal models of inflammatory diseases.

Research Area

Cell Biology, Immunology & Inflammation, Neuroscience

Key Properties

• CAS Number: 256373-96-3
• MW: 426.46
• Purity: >98%
• Formula: C₂₀H₂₃N₂O₅S • Na
• SMILES: [Na+].CC(C)(O)c1coc(c1)S(=O)(=O)[N-]C(=O)Nc1c2CCCc2cc2CCCc12
• Target: Inflammasome
• Solubility: Soluble in DMSO (up to 40 mg/ml) or in Water (up to 30 mg/ml).

Bioactivity

• Target IC50:
  NLRP3:7.5 nM
• In Vivo:
  METHODS: To detect anti-NLRP3 activity in vivo, MCC950 sodium (20 mg/kg) was injected intraperitoneally into a mouse model of the human CAPS disease MWS once daily for four weeks. RESULTS: MCC950 rescued the CAPS mouse model and inhibited NLRP3 in human MWS cells. METHODS: To investigate the pharmacological effects on experimental spinal cord injury models in vivo and neuronal injury in vitro, MCC950 sodium (10-50 mg/kg) was intraperitoneally injected into C57BL/6 mice with spinal cord injury (SCI). RESULTS: MCC950 improved grip strength, hindlimb movement, spinal cord edema, and pathological damage in SCI mice. It exerted this effect by blocking NLRP3 inflammatory vesicle assembly and the release of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-18.
• In Vitro:
  METHODS: Mouse bone marrow-derived macrophages BMDM were stimulated with LPS (10 ng/mL) for 3 h, stimulated with MCC950 sodium (1-1000 nM) for 30 min, and then treated with ATP (5 mM) for 1 h. Levels of IL-1β and TNF-α were measured by ELISA. RESULTS: MCC950-treated cells dose-dependently inhibited the release of IL-1β in BMDM, and LPS-dependent TNF-α secretion was not impaired by MCC950. MCC950 was used in the treatment of BMDM cells. METHODS: Mouse macrophages, human coronary artery endothelial cells and smooth muscle cells were treated with MCC950 sodium (0.02-20 μM) for 3 days, and cell viability was measured by Alamar Blue assay. RESULTS: MCC950 sodium had no toxic effect on the three cells.
• Cell Research:
  MCC950 is dissolved in DMSO and stored, and then diluted with appropriate media before use. BMDM are seeded at 5×105/mL or 1×106/mL, HMDM at 5×105/mL and PBMC at 2×106/mL or 5×106/mL in 96 well plates. The following day the overnight medium is replaced and cells are stimulated with 10 ng/mL LPS from Escherichia coli serotype EH100 (ra) TLRgrad for 3 h. Medium is removed and replaced with serum free medium (SFM) containing DMSO (1:1,000), MCC950 (0.001-10 μM), glyburide (200 μM), Parthenolide (10 μM) or Bayer cysteinyl leukotriene receptor antagonist 1-(5-carboxy-2{3-[4-(3-cyclohexylpropoxy)phenyl]propoxy}benzoyl)piperidine-4-carboxylic acid (40 μM) for 30 min. Cells are then stimulated with inflammasome activators: 5 mM adenosine 5'-triphosphate disodium salt hydrate (ATP) (1 h), 1 μg/mL Poly(deoxyadenylic-thymidylic) acid sodium salt (Poly dA:dT) transfected with Lipofectamine 200 (3-4 h), 200 μg/mL MSU (overnight) and 10 μM nigericin (1 h) or S. typhimurium UK-1 strain. Cells are also stimulated with 25 μg/mL Polyadenylic-polyuridylic acid (4 h). For non-canonical inflammasome activation cells are primed with 100 ng/mL Pam3CSK4 for 4 h, medium is removed and replaced with SFM containing DMSO or MCC950 and 2 μg/mL LPS is transfected using 0.25% FuGENE for 16 h. Supernatants are removed and analysed using ELISA kits. LDH release is measured using the CytoTox96 non-radioactive cytotoxicity assay.
• Animal Research:
  C57BL/6 mice were injected intraperitoneally with 50 mg/kg MCC950.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CRID3; CP-456773 sodium salt

Compound Identifiers

PubChem CID

91826093